文献速递白血病

接受帕纳替尼或伊马替尼治疗的费城染色体阳性急性淋巴细胞白血病患者的患者报告结局:PhALLCON试验结果

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
PubMed 文献 · Leukemia · 2025-04-16

3期PhALLCON试验(NCT03589326)在初诊费城染色体阳性(Ph+)急性淋巴细胞白血病成人患者中比较帕纳替尼与伊马替尼,本文报告探索性患者报告结局(PRO)。分析纳入238例患者(帕纳替尼159例,伊马替尼79例),采用FACT-Leu和EQ-5D-5L评估;帕纳替尼在FACT-LeuS、TOI和FACT-Leu总分等主要领域的最小二乘均值变化优于伊马替尼。

要点

  • 帕纳替尼组在FACT-LeuS、TOI和FACT-Leu总分的最小二乘均值变化优于伊马替尼组
  • 帕纳替尼组在关键指标上达到确认改善的中位时间短于伊马替尼组
  • 帕纳替尼组患者报告受治疗副作用困扰的程度倾向于更低(FACT-GP5)

核心结论

  • 帕纳替尼可能对健康相关生活质量产生有利影响,支持其作为Ph+ ALL一线治疗。

研究设计与样本

  • 3期PhALLCON试验(NCT03589326)的探索性患者报告结局分析,纳入238例患者(帕纳替尼159例,伊马替尼79例),均至少有1次PRO评估。

主要发现

  • 从基线至诱导结束(EOI),帕纳替尼组在FACT-LeuS、TOI和FACT-Leu总分的最小二乘均值变化优于伊马替尼组,差异显著且有临床意义。
  • 从基线至巩固结束(EOC),除FACT-LeuS外,帕纳替尼组在主要领域的最小二乘均值变化均优于伊马替尼组。
  • 帕纳替尼组在关键指标上达到确认改善的中位时间短于伊马替尼组。
  • 帕纳替尼组患者报告受治疗副作用困扰的程度倾向于更低(FACT-GP5)。

关键数值与推荐

  • 主要PRO领域包括FACT-G身体健康、FACT-Leu子量表(FACT-LeuS)、试验结局指数(TOI)、FACT-Leu总分、FACT-G总分和EQ-5D视觉模拟量表。
  • 从基线至EOI,帕纳替尼组在FACT-LeuS、TOI和FACT-Leu总分的最小二乘均值变化优于伊马替尼组,差异显著且有临床意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the Phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy and comparable safety profile versus imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Here we report patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L. Primary PRO domains included FACT-G physical well-being, FACT-Leu subscale (FACT-LeuS), Trial Outcome Index (TOI), FACT-Leu total score, FACT-G total score, and EQ-5D visual analogue scale. Differences in least-squares mean score changes from baseline to the end of induction (EOI)/consolidation (EOC) and time to confirmed improvement/deterioration were analyzed. Overall treatment tolerability was assessed using the FACT-GP5. Analyses included 238 patients (ponatinib 159, imatinib 79) with ≥1 PRO assessment. Least-squares mean changes from baseline favored ponatinib, with significant and meaningful differences in FACT-LeuS, TOI, and FACT-Leu total score at EOI and across the primary domains except for FACT-LeuS at EOC. Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures. Ponatinib-treated patients tended to report being less bothered by treatment side effects as assessed by FACT-GP5. These findings highlight ponatinib's potentially favorable impact on health-related quality of life, supporting its use as frontline treatment for Ph+ ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ashaye A, Shi L, Aldoss I, et al. Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial. Leukemia. 2025. PMID: 40240572. doi:10.1038/s41375-025-02608-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。